News

Welter Family Fellowship

Veronica Hubble, a graduate student in the Melander lab, is the first recipient of the Welter Family graduate fellowship for research on Cystic Fibrous. The Welter Family Fellowship in Science provides financial support to conduct research during the 2019 academic year. This fellowship is aimed at facilitating discoveries in cystic fibrosis research, which can include mechanistic studies, drug development, and/or related diseases that affect those with CF (eg. infections of the lung). Veronica’s proposal was entitled “Using small molecule adjuvants to combat antibiotic resistant bacteria in cystic fibrosis.”

Read More

Spring 2019 The Warren Roundup

As the 2018 academic year comes to an end, a summary of this year's accomplishments is provided in the annual Warren Roundup. First of all, several lead compounds have been identified by Notre Dame researchers and are undergoing preclinical evaluation, in hopes of identifying investigational new drugs (IND) for clinical evaluation.  …

Read More

Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM

Read More

New Hope for the Treatment of Diabetic Foot Ulcers

In America, more than a million people suffer from diabetic foot ulcers.

In Latin, SalvePeds means “saving feet.” 

And in SalvePeds, a new IDEA Center startup managed and marketed by a team of graduate students at the University of Notre Dame, patients may soon have a more effective option to treat diabetic foot ulcers and prevent some of the 100,000 amputations the condition necessitates every year.…

Read More

Spring 2018 Warren Roundup Published

Welcome to the first edition of the Warren Roundup, wherein an attempt is made to summarize accomplishments by members of the Warren Family Research Center for Drug Discovery. In addition, you will find below a succinct summary of the services provided by each of the three scientific cores (synthesis, computational, and biological). Not only do I invite you to provide updates for inclusion in upcoming issues, but I also encourage you to learn more about the Warren Center cores and how they can help expedite your research.…

Read More

Indiana CTSI launching new program to engage Indiana residents in improving health through research

The Indiana Clinical and Translational Sciences Institute (CTSI), a research partnership among Indiana University, Purdue University and the University of Notre Dame, has launched a new program called “All IN for Health” to help grow public awareness of the state’s current health challenges and to invite the public’s participation into research studies taking place at our academic partner institutions.

Read More

Apply Today for these open Indiana CTSI Grants

There are currently four open Indiana Clinical and Translational Sciences Institute grant opportunities.

The Indiana CTSI is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP).

Read More

Tuberculosis Research Sheds Light on Disease-related Protein

The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease. 

Read More

Warren Center faculty member presents at the Solutions for Drug-Resistant Infections Conference (SDRI 2017)

Professsor Marv Miller presented the seminar, “Conjugation of an acinetobacter selective sideophore to Daptomycin generates a sideromycin with potent activity against acinetobacter baumannii” at the Antimicrobial Drug Discovery Symposium at the Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia, April 3-5. SDRI 2017 brought together leading scientific, medical and…

Read More

Expanding new areas of rare disease research at Notre Dame

Rarediseaseday250

Coinciding with the World Rare Disease Day, Notre Dame acknowledges a recent, generous gift from Notre Dame parents David and Cathleen Reisenauer of Morgan Hill, Calif., which will allow the Warren Family Research Center for Drug Discovery and Development to initiate a new area of research, focusing on the rare disease glycogen storage disease type III (GSDIII), also known as Cori Disease.

Read More

Rare Disease Day 2017 and Rare Disease Research within the Warren Center

Rare Disease Day takes place annually on the last day of February. Its goal is to raise awareness amongst the general public and policy-makers. Global Genes maintains the RARE List™ of 7,000 rare diseases defined in the United States where a prevalence of less than 200,000 cases is the primary criteria. With about 25M Americans affected by a rare disease and the potential to increase our understanding of more common afflictions, rare disease research is a key to better health for all of us.…

Read More